Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter clinical trials

Explore recruiting low risk myelodysplastic syndromes failing erythropoiesis stimulating agents and luspatercept or ineligible for the latter clinical trials.

Recruiting low risk myelodysplastic syndromes failing erythropoiesis stimulating agents and luspatercept or ineligible for the latter studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ATOMYELO: Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes failing Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter trials by city

Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Toronto Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Vancouver Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Montreal Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Calgary Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Edmonton Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Ottawa Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Winnipeg Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Quebec City Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Hamilton Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Kitchener Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in London Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Halifax Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in New York Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Los Angeles Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Chicago Low Risk Myelodysplastic Syndromes Failing Erythropoiesis Stimulating Agents And Luspatercept Or Ineligible For The Latter in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease